Larotinib for advanced esophageal cancer with high EGFR
Part of Cancer, Digestive system clinical trials.
This phase 3 trial tests larotinib, a targeted cancer medicine, for people with advanced or recurrent esophageal cancer that has high EGFR. It aims to see if it works better than standard treatment approaches after the cancer has progressed twice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and you have esophageal squamous cell cancer confirmed by a lab report or scans
- Your cancer has grown or spread despite two prior standard treatments
- Your general strength is good (ECOG 0 or 1), and you have at least 3 months to live
- Your tumor must test positive for high EGFR from a tissue sample (or you can do a new biopsy if needed)
- You can swallow pills/medicine, and your organs (like blood, liver, and kidneys) function well enough for treatment
- You are able and willing to join the study, follow the schedule closely, and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study (Phase 1) tests how larotinib moves through the body and is handled by the liver in people with normal liver function or mild to moderate liver impairment. The goal is to understand dosing and safety in different liver conditions.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people whose esophageal cancer didn't respond to or couldn't tolerate the first treatment. The goal is to see if this second-line therapy can shrink tumors or slow their growth.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.